What's Hot
View all perspectives
sheila RHEUMarampa
4 years ago
Tofa for RA by the grp of Dr. Atul Deodhar:
>Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16
>Primary & secondary endpts met
>No new safety signals reported
@Rheumnow #ACR20 https://t.co/G9U5cCQU7K
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint of patients with inflammatory back pain in trying to determine if a patient has SpA! #ACR20 @RheumNow https://t.co/gwySNvfSH5
Lifestyle and Risk of RA, Lupus: Dr. Janet Pope
Dr. Janet Pope reviews abstracts #1198 and #1473 presented at the 2020 ACR annual meeting.
Elizabeth Graef SituationRheum
4 years ago
📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future
👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity
#ACRAmbassador https://t.co/AM2mfYmAtI
Elizabeth Graef SituationRheum
4 years ago
And we're off! #ACR20 year in review
⭐️@philseo's #Vasculitis lecture⭐️
Take home lessons/ remaining questions from GiACTA ⬇️
#ACRambassador https://t.co/7C9QxbUeNH
Elizabeth Graef SituationRheum
4 years ago
📌More #Vasculitis pearls from #ACR20 Year in Review
#PEXIVAS in a nutshell ⬇️
#ACRambassador https://t.co/PnoP7QIiYs
Dr Philip Robinson philipcrobinson
4 years ago
Pfizer vaccine data potentially shows >90% effectiveness via @nytimes https://t.co/jwVkmbMaTL
Suleman Bhana, MD DrBhana
4 years ago
from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives.
#ACRambassador https://t.co/ARo762Vozp
Vaneet K Sandhu, MD vksandhumd
4 years ago
Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
Bharat Kumar BharatKumarMD
4 years ago
Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with finals! https://t.co/3yLgqqC0Yy
Vaneet K Sandhu, MD vksandhumd
4 years ago
ARCH study -- n~4100
Romo vs Alendronate x 12 mo
Alendronate 12-24 mo
RRR 38% https://t.co/d0G7x4TqUT
Vaneet K Sandhu, MD vksandhumd
4 years ago
Hypophosphatasia
- CPPD/chondrocal, enthesop'y, DISH, exostoses
- DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM
Rx - asfotase alpha- bone targeted replac't Rx
#ACR20 #ACRambassador https://t.co/FJ1355MdKG
Sebastian E. Sattui MD, MS SattuiSEMD
4 years ago
#ACR20 Abstracts on #ILD
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m
#1051 ➡️ 50 with IPAF: >70% stable or improved at 12m
#1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX
#ACRambassador https://t.co/klfVwIH5b6
Steven Echard, CAE StevenEchard
4 years ago
Over 20,000 tweets and 65 Million+ Impressions Check out the details at https://t.co/Z6X1EeOsnr https://t.co/OtqWZCiu6h
Poster Hall